Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Many women choose Depo-Provera for birth control because it is easy to use and very effective. However, a significant number of Depo-Provera users experience irregular bleeding during the first 90 days. Many users discontinue after their first injection due to irregular bleeding. This study will evaluate the effect of using an estrogen vaginal ring during the first 90 days of Depo-Provera use to see if it is acceptable to women and whether it decreases irregular bleeding during the first 90 days of use and increases continuation to a second injection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Estrogens; Medroxyprogesterone; Medroxyprogesterone Acetate; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Women age 18 or older who are initiating Depo-Provera for contraception

• English or Spanish-speaking

• Have a negative urine pregnancy test

Exclusion Criteria:

• Contraindications to either Depo-Provera or Femring (estrogen vaginal ring)

• Have used Depo-Provera or Mirena in the prior 6 months

• Have had an induced abortion, spontaneous abortion, or birth in prior 8 weeks